Assembly Biosciences Inc (NASDAQ:ASMB) reached a new 52-week low during trading on Monday . The company traded as low as $13.13 and last traded at $14.80, with a volume of 81780 shares traded. The stock had previously closed at $18.79.
ASMB has been the subject of a number of research analyst reports. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Tuesday, January 1st. Chardan Capital reaffirmed a “hold” rating and issued a $30.00 target price on shares of Assembly Biosciences in a research report on Monday. Finally, Zacks Investment Research raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research report on Thursday, February 21st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $43.00.
The stock has a market capitalization of $500.77 million, a P/E ratio of -3.71 and a beta of 1.75.
Large investors have recently bought and sold shares of the business. Legal & General Group Plc grew its position in shares of Assembly Biosciences by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 3,289 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 616 shares during the period. Metropolitan Life Insurance Co. NY grew its position in shares of Assembly Biosciences by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,073 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 5,524 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Assembly Biosciences during the 3rd quarter valued at $407,000. BlueMountain Capital Management LLC grew its position in shares of Assembly Biosciences by 100.3% during the 3rd quarter. BlueMountain Capital Management LLC now owns 14,601 shares of the biopharmaceutical company’s stock valued at $542,000 after acquiring an additional 7,313 shares during the period. Finally, Two Sigma Investments LP bought a new stake in shares of Assembly Biosciences during the 4th quarter valued at $336,000. 83.62% of the stock is owned by institutional investors and hedge funds.
About Assembly Biosciences (NASDAQ:ASMB)
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Further Reading: Market Capitalization – What it Means for Investors
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.